Compare Boeing Co (BA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Incyte Corporation — how do they compare? Boeing Co trades at $234 (market cap $184.35B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Boeing Co is far larger — about 7.5× Incyte Corporation's market cap, and Boeing Co pays a 0.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BA | INCY | |
|---|---|---|
Market Cap | $184.35B | $24.54B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $129.93 |
52-Week Low | $179.12 | $81.61 |
Enterprise Value | $210.23B | $20.04B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.
The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
